

National Radiology Data Registry

Facility Report, Mar 2021

Public Facility
(Facility ID: 100853)



nrdr.acr.org



This page is intentionally blank.

Lung Cancer Screening Registry Report from the American College of Radiology

We are pleased to release the Jan-Mar 2021 quarterly Lung Cancer Screening Registry reports. The PDF report contains the following:

Section 1: Facility level data, 2021

This section provides a list of LCSR measures calculated from data submitted during Jan-Mar 2021. We provide a comparison of your measures with the LCSR registry and similar facilities in terms of facility type, location and census division. Section 1 is provided only for those facilities that have submitted data during 2021.

Section 2: Facility level data, 2020

This section provides a list of LCSR measures calculated from data submitted during Jan-Dec 2020. We provide a comparison of your measures with the LCSR registry and similar facilities in terms of facility type, location and census division. Section 2 is provided only for those facilities that submitted data during 2020.

Demographic Data


The bar charts describe demographic data of all the facilities that contributed data during 2020 and 2021.










Maintenance of Certification (MOC):Practice Quality Improvement (PQI).

We have listed the physicians participating in LCSR at your facility and their NPI's.

We exclude exams without NPI information for the interpreting radiologist as it is a required field for CMS submission, in our role as a CMS approved registry.

LCSR Facilities



Census Division	 New England Division	 Middle Atlantic Division	 East North Central Division
	 West North Central Division	 South Atlantic Division	 East South Central Division
	 West South Central Division	 Mountain Division	 Pacific Division

Black dots indicate LCSR facilities that contributed data for this report

LCSR Measure Definitions

Measure	Description
Appropriateness of screening by USPSTF criteria	Percent of screening population who are adults aged 55 to 80 years, have a 30 pack-year smoking history, and currently smoke or have quit within the past 15 years.
Smoking cessation offered	Percent of patients who are offered smoking cessation guidance.
Smoking cessation offered among current smokers	Percent of current smokers who are offered smoking cessation guidance.
Radiation exposure 1 Mean CT DIvol - overall	Mean Volumetrics CT Dose Index (CT DIvol) across all screening exams performed.
Radiation exposure 1 Mean CT DIvol underweight (BMI <18.5)	Mean Volumetrics CT Dose Index (CT DIvol) across all screening exams performed on underweight patients (BMI<18.5).
Radiation exposure 1 Mean CT DIvol normal (BMI of 18.5–24.9)	Mean Volumetrics CT Dose Index (CT DIvol) across all screening exams performed on normal weight patients (BMI of 18.5-24.9).
Radiation exposure 1 Mean CT DIvol overweight (BMI of 25–29.9)	Mean Volumetrics CT Dose Index (CT DIvol) across all screening exams performed on overweight patients (BMI of 25-29.9).
Radiation exposure 1 Mean CT DIvol obese class I (BMI of 30-34.9)	Mean Volumetrics CT Dose Index (CT DIvol) across all screening exams performed on class I obese patients (BMI of 30-34.9).
Radiation exposure 1 Mean CT DIvol obese class II (BMI of 35-39.9)	Mean Volumetrics CT Dose Index (CT DIvol) across all screening exams performed on class II obese patients (BMI of 35-39.9).
Radiation exposure 1 Mean CT DIvol obese class III (BMI of 40 or greater)	Mean Volumetrics CT Dose Index (CT DIvol) across all screening exams performed on class III obese patients (BMI of 40 or greater).
Radiation exposure 1 Mean CT DIvol - routine chest exams	Mean Volumetrics CT Dose Index (CT DIvol) across routine chest exams performed.
Radiation exposure 1 Mean CT DIvol - other than routine chest exam	Mean Volumetrics CT Dose Index (CT DIvol) across all other than routine chest exams performed.
Radiation exposure (DLP)	Mean Dose Length Product (DLP) across all screening exams performed.
Radiation exposure 2 Mean DLP underweight (BMI <18.5)	Mean Dose Length Product (DLP) across all screening exams performed on underweight patients (BMI<18.5).
Radiation exposure 2 Mean DLP normal (BMI of 18.5–24.9)	Mean Dose Length Product (DLP) across all screening exams performed on normal weight patients (BMI of 18.5-24.9).
Radiation exposure 2 Mean DLP overweight (BMI of 25–29.9)	Mean Dose Length Product (DLP) across all screening exams performed on overweight patients (BMI of 25-29.9).




LCSR Measure Definitions

Measure	Description
Radiation exposure 2 Mean DLP obese class I (BMI of 30-34.9)	Mean Dose Length Product (DLP) across all screening exams performed on class I obese patients (BMI of 30-34.9).
Radiation exposure 2 Mean DLP obese class II (BMI of 35-39.9)	Mean Dose Length Product (DLP) across all screening exams performed on class II obese patients (BMI of 35-39.9).
Radiation exposure 2 Mean DLP obese class III (BMI of 40 or greater)	Mean Dose Length Product (DLP) across all screening exams performed on class III obese patients (BMI of 40 or greater).
Radiation exposure 2 Mean DLP routine chest exams	Mean Dose Length Product (DLP) across all routine chest exams performed.
Radiation exposure 2 Mean DLP other than routine chest exams	Mean Dose Length Product (DLP) across all other than routine chest exams performed.
Lung Cancer Screening Abnormal Interpretation Rate (Recall Rate)	Percent of screening exams that have a Lung-RADS assessment of 3, 4a, 4b, or 4x (and lead to additional imaging or biopsy).
Lung Cancer Screening Abnormal Interpretation Rate (Recall Rate) during baseline exam	Percent of baseline screening exams that have a Lung-RADS assessment of 3, 4a, 4b, or 4x (and lead to additional imaging or biopsy).
Lung Cancer Screening Abnormal Interpretation Rate (Recall Rate) during annual exam	Percent of annual screening exams that have a Lung-RADS assessment of 3, 4a, 4b, or 4x (and lead to additional imaging or biopsy).
Lung Cancer Screening Cancer Detection Rate (CDR)	Number per 1000 screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of cancer within 12 months.
CDR for prevalent cancers, detected at baseline exam	Number per 1000 baseline (first visit) screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of cancer within 12 months.
CDR for incident cancers, detected at annual exam	Number per 1000 annual (not baseline) screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of cancer within 12 months.
CDR for stage 0	Number per 1000 screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of cancer stage 0 within 12 months.
CDR for stage IA, IA1, IA2, IA3, IB	Number per 1000 screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of cancer stage 1 within 12 months.
CDR for stage IIA, IIB	Number per 1000 screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of cancer stage 2 within 12 months.
CDR for stage IIIA, IIIB, IIIC	Number per 1000 screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of cancer stage 3 within 12 months.

LCSR Measure Definitions

Measure	Description
CDR for stage IV, IVA, IVB	Number per 1000 screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of cancer stage 4 within 12 months.
CDR for unknown stage	Number per 1000 screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a tissue diagnosis of cancer of unknown stage within 12 months.
CDR for presumptive case	Number per 1000 screening exams that had both a Lung-RADS assessment category of 3 or 4a, 4b, 4x and a non-histology diagnosis of cancer within 12 months.
PPV1	Percent of screening exams with a Lung-RADS assessment of 3, 4a, 4b, or 4x that had a tissue diagnosis of cancer diagnosis within 12 months.
PPV1 for lung cancers detected on percutaneous biopsies	Percent of screening exams with a Lung-RADS assessment of 3, 4a, 4b, or 4x that had a tissue diagnosis of cancer diagnosis within 12 months, detected on percutaneous biopsies.
PPV1 for lung cancers detected on bronchoscopies	Percent of screening exams with a Lung-RADS assessment of 3, 4a, 4b, or 4x that had a tissue diagnosis of cancer diagnosis within 12 months, detected on bronchoscopies.
PPV1 for surgically detected lung cancers	Percent of screening exams with a Lung-RADS assessment of 3, 4a, 4b, or 4x that had a tissue diagnosis of cancer diagnosis within 12 months, detected on surgical interventions.
PPV2a	Percent of screening exams that had a Lung-RADS assessment category of 3, 4a (typically associated with additional CT recommendation or PET/CT recommendation) that had a tissue diagnosis of cancer within 12 months.
PPV2b	Percent of screening exams that had a Lung-RADS assessment category of 4B or 4X (typically associated with biopsy recommendation) that had a tissue diagnosis of cancer within 12 months.
PPV3	Percent of screening exams that had a Lung-RADS assessment category of 4B or 4X (typically associated with biopsy recommendation) and with record of biopsy performed that had a tissue diagnosis of cancer within 12 months.

LCSR Facility Characteristics : 2020-2021



Section 1 Facility Report: Preliminary data on exams performed during Jan-Mar 2021

***Facility 100853 National Comparison
Jan-Mar 2021***

		2021				2020	
Measure		Your Facility (100853)		All LCSR		All LCSR	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
All Exams		.	50406	.	168013	.	652366
Appropriateness of screening by USPSTF criteria (%)		91.37	46056 / 50406	91.39	153546 / 168013	91.18	594859 / 652366
Smoking cessation counselling offered (%)		74.35	37476 / 50406	73.95	124240 / 168013	75.18	490437 / 652366
	counselling offered among current smokers (%)	81.01	23549 / 29069	80.46	78370 / 97401	81.70	303845 / 371922
Radiation exposure - Mean CTDIvol	Overall (mGy)	3.27	NA / 49879	3.25	NA / 166231	3.34	NA / 643835
	underweight (BMI <18.5)(mGy)	2.28	NA / 1216	2.33	NA / 4089	2.47	NA / 15587
	normal (BMI of 18.5-24.9)(mGy)	2.54	NA / 11186	2.54	NA / 37701	2.61	NA / 152473
	overweight (BMI of 25-29.9)(mGy)	3.20	NA / 15908	3.03	NA / 52736	3.14	NA / 203420
	obese class I (BMI of 30-34.9)(mGy)	3.52	NA / 10895	3.61	NA / 36213	3.76	NA / 135686
	obese class II (BMI of 35-39.9)(mGy)	3.61	NA / 4888	3.76	NA / 16401	3.76	NA / 61063
	obese class III (BMI of 40 or greater)(mGy)	3.96	NA / 3497	4.03	NA / 11329	4.36	NA / 41914
	routine chest exam (mGy)	5.51	NA / 515	5.17	NA / 1744	4.66	NA / 9214
	low dose CT chest exam (mGy)	3.25	NA / 49209	3.23	NA / 163981	3.33	NA / 630897
Radiation exposure - Mean DLP	Overall	95.25	NA / 49862	94.83	NA / 166159	94.67	NA / 644565
	underweight (BMI <18.5)(mGy-cm)	71.23	NA / 1219	70.25	NA / 4090	70.62	NA / 15624
	normal (BMI of 18.5-24.9)(mGy-cm)	76.66	NA / 11185	76.00	NA / 37710	76.81	NA / 152692
	overweight (BMI of 25-29.9)(mGy-cm)	89.04	NA / 15914	89.31	NA / 52750	89.30	NA / 203641
	obese class I (BMI of 30-34.9)(mGy-cm)	105.87	NA / 10895	104.67	NA / 36215	104.68	NA / 135827
	obese class II (BMI of 35-39.9)(mGy-cm)	1.00	NA / 4893	1.00	NA / 16399	1.00	NA / 61109
	obese class III (BMI of 40 or greater)(mGy-cm)	128.61	NA / 3497	129.41	NA / 11329	129.63	NA / 41947
	routine chest exam (mGy-cm)	164.25	NA / 518	164.99	NA / 1753	141.72	NA / 9239
	low dose CT chest exam (mGy-cm)	94.54	NA / 49188	94.08	NA / 163900	94.00	NA / 631603
Abnormal Interpretation Rate (%)	(Lung-RADS 3, 4a, 4b, 4x)	12.81	6459 / 50406	13.02	21872 / 168013	13.58	88610 / 652366
	Abnormal Interpretation Rate, at baseline exam (%)	16.16	3782 / 23397	16.35	12765 / 78075	16.61	51723 / 311480
	Abnormal Interpretation Rate, at annual exam (%)	9.84	2546 / 25877	10.06	8676 / 86253	10.69	35028 / 327777

***Facility 100853 National Comparison
Jan-Mar 2021***

		2021				2020	
Measure		Your Facility (100853)		All LCSR		All LCSR	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
Cancer Detection Rate (CDR) per 1000		1.75	88 / 50406	1.75	294 / 168013	2.82	1842 / 652366
	prevalent cancers, detected at baseline exam	2.35	55 / 23397	2.28	178 / 78075	3.47	1081 / 311480
	incident cancers, detected at annual exam	1.47	38 / 25877	1.47	127 / 86253	2.49	815 / 327777
	stage 0	NA	NA / 91	3	NA / 293	17	NA / 1925
	stage IA, IA1, IA2, IA3, IB	30.77	28 / 91	31.06	91 / 293	38.65	744 / 1925
	stage IIA, IIB	7.69	7 / 91	7.51	22 / 293	8.05	155 / 1925
	stage IIIA, IIIB, IIIC	12.09	11 / 91	14.33	42 / 293	14.18	273 / 1925
	stage IV, IVA, IVB	13.19	12 / 91	9.90	29 / 293	9.61	185 / 1925
	stage unknown	35.16	32 / 91	36.18	106 / 293	28.62	551 / 1925
	presumptive case	NA	0 / 0	63.34	306 / 168013	65.01	1924 / 652366
Positive Predictive Value 1 (PPV1)(%)		1.36	88 / 6459	1.34	294 / 21872	2.08	1842 / 88610
	lung cancers detected on percutaneous biopsies (%)	65.28	47 / 72	58.33	140 / 240	60.09	843 / 1403
	lung cancers detected on bronchoscopies (%)	45.45	30 / 66	46.60	96 / 206	49.27	504 / 1023
	surgically detected lung cancers (%)	85.00	17 / 20	83.16	79 / 95	81.89	701 / 856
Positive Predictive Value 2a (PPV2a) (%)		0.29	15 / 5233	0.25	45 / 17778	0.67	480 / 72057
Positive Predictive Value 2b (PPV2b) (%)		5.95	73 / 1226	6.08	249 / 4094	8.23	1362 / 16553
Positive Predictive Value 3 (PPV3) (%)		64.22	70 / 109	63.34	235 / 371	65.01	1312 / 2018

Facility 100853 Regional Comparison
Jan-Mar 2021

		2021							
Measure		Your Facility (100853)		Metropolitan		Freestanding		Missing	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
All Exams		.	50406	.	66339	.	33663	.	
Appropriateness of screening by USPSTF criteria (%)		91.37	46056 / 50406	91.09	60427 / 66339	91.73	30879 / 33663		
Smoking cessation counselling offered (%)		74.35	37476 / 50406	70.87	47013 / 66339	75.26	25335 / 33663		
	counselling offered among current smokers (%)	81.01	23549 / 29069	77.63	29191 / 37603	80.19	15588 / 19439		
Radiation exposure - Mean CTDIvol	Overall (mGy)	3.27	NA / 49879	3.40	NA / 65492	2.83	NA / 33202		
	underweight (BMI <18.5)(mGy)	2.28	NA / 1216	2.15	NA / 1547	1.93	NA / 689		
	normal (BMI of 18.5-24.9)(mGy)	2.54	NA / 11186	2.54	NA / 15186	2.29	NA / 7836		
	overweight (BMI of 25-29.9)(mGy)	3.20	NA / 15908	3.13	NA / 20923	2.51	NA / 11019		
	obese class I (BMI of 30-34.9)(mGy)	3.52	NA / 10895	3.89	NA / 14104	3.17	NA / 6814		
	obese class II (BMI of 35-39.9)(mGy)	3.61	NA / 4888	3.99	NA / 6232	3.41	NA / 2997		
	obese class III (BMI of 40 or greater)(mGy)	3.96	NA / 3497	4.40	NA / 4357	3.79	NA / 2080		
	routine chest exam (mGy)	5.51	NA / 515	4.48	NA / 937	8.27	NA / 196		
	low dose CT chest exam (mGy)	3.25	NA / 49209	3.39	NA / 64438	2.79	NA / 32879		
Radiation exposure - Mean DLP	Overall	95.25	NA / 49862	93.87	NA / 65409	92.75	NA / 33168		
	underweight (BMI <18.5)(mGy-cm)	71.23	NA / 1219	68.52	NA / 1548	69.13	NA / 688		
	normal (BMI of 18.5-24.9)(mGy-cm)	76.66	NA / 11185	74.98	NA / 15182	74.52	NA / 7826		
	overweight (BMI of 25-29.9)(mGy-cm)	89.04	NA / 15914	88.23	NA / 20924	87.48	NA / 11018		
	obese class I (BMI of 30-34.9)(mGy-cm)	105.87	NA / 10895	102.78	NA / 14098	107.07	NA / 6813		
	obese class II (BMI of 35-39.9)(mGy-cm)	1.00	NA / 4893	1.00	NA / 6235	1.00	NA / 2996		
	obese class III (BMI of 40 or greater)(mGy-cm)	128.61	NA / 3497	128.40	NA / 4361	122.80	NA / 2078		
	routine chest exam (mGy-cm)	164.25	NA / 518	139.91	NA / 940	270.53	NA / 196		
	low dose CT chest exam (mGy-cm)	94.54	NA / 49188	93.18	NA / 64351	91.65	NA / 32845		

***Facility 100853 Regional Comparison
Jan-Mar 2021***

		2021							
Measure		Your Facility (100853)		Metropolitan		Freestanding		Missing	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
Abnormal Interpretation Rate (%)	(Lung-RADS 3, 4a, 4b, 4x)	12.81	6459 / 50406	12.52	8304 / 66339	13.57	4569 / 33663		
	Abnormal Interpretation Rate, at baseline exam (%)	16.16	3782 / 23397	15.57	4708 / 30234	16.92	2809 / 16598		
	Abnormal Interpretation Rate, at annual exam (%)	9.84	2546 / 25877	9.81	3337 / 34028	10.28	1686 / 16403		
Cancer Detection Rate (CDR) per 1000		1.75	88 / 50406	1.94	129 / 66339	0.59	20 / 33663		
	prevalent cancers, detected at baseline exam	2.35	55 / 23397	2.41	73 / 30234	0.84	14 / 16598		
	incident cancers, detected at annual exam	1.47	38 / 25877	1.73	59 / 34028	0.49	8 / 16403		
	stage 0	NA	NA / 91	2	NA / 127	0	NA / 23		
	stage IA, IA1, IA2, IA3, IB	30.77	28 / 91	30.71	39 / 127	30.43	7 / 23		
	stage IIA, IIB	7.69	7 / 91	11.81	15 / 127	0.00	0 / 23		
	stage IIIA, IIIB, IIIC	12.09	11 / 91	14.96	19 / 127	8.70	2 / 23		
	stage IV, IVA, IVB	13.19	12 / 91	12.60	16 / 127	17.39	4 / 23		
	stage unknown	35.16	32 / 91	28.35	36 / 127	43.48	10 / 23		
	presumptive case	NA	0 / 0	64.78	132 / 66339	47.06	22 / 33663		
Positive Predictive Value 1 (PPV1)(%)		1.36	88 / 6459	1.55	129 / 8304	0.44	20 / 4569		
	lung cancers detected on percutaneous biopsies (%)	65.28	47 / 72	61.29	57 / 93	45.00	9 / 20		
	lung cancers detected on bronchoscopies (%)	45.45	30 / 66	47.96	47 / 98	29.63	8 / 27		
	surgically detected lung cancers (%)	85.00	17 / 20	81.25	39 / 48	80.00	4 / 5		
Positive Predictive Value 2a (PPV2a) (%)		0.29	15 / 5233	0.31	21 / 6715	0.08	3 / 3780		
Positive Predictive Value 2b (PPV2b) (%)		5.95	73 / 1226	6.80	108 / 1589	2.15	17 / 789		
Positive Predictive Value 3 (PPV3) (%)		64.22	70 / 109	64.78	103 / 159	47.06	16 / 34		

Section 2 Facility Report: Exams performed during Jan-Dec 2020 with follow-up through Mar 2021

***Facility 100853 National Comparison
Jan-Dec 2020 with follow-up through Mar 2021***

		2020			
Measure		Your Facility (100853)		All LCSR	
		Rate	Num-Den	Rate	Num-Den
All Exams		.	195712	.	652366
Appropriateness of screening by USPSTF criteria (%)		91.17	178424 / 195712	91.18	594859 / 652366
Smoking cessation counselling offered (%)		75.14	147049 / 195712	75.18	490437 / 652366
	counselling offered among current smokers (%)	81.64	90982 / 111438	81.70	303845 / 371922
Radiation exposure - Mean CTDIvol	Overall (mGy)	3.36	NA / 193108	3.34	NA / 643835
	underweight (BMI <18.5)(mGy)	2.44	NA / 4648	2.47	NA / 15587
	normal (BMI of 18.5-24.9)(mGy)	2.59	NA / 45891	2.61	NA / 152473
	overweight (BMI of 25-29.9)(mGy)	3.15	NA / 61049	3.14	NA / 203420
	obese class I (BMI of 30-34.9)(mGy)	3.74	NA / 40572	3.76	NA / 135686
	obese class II (BMI of 35-39.9)(mGy)	3.89	NA / 18211	3.76	NA / 61063
	obese class III (BMI of 40 or greater)(mGy)	4.60	NA / 12579	4.36	NA / 41914
	routine chest exam (mGy)	4.48	NA / 2765	4.66	NA / 9214
	low dose CT chest exam (mGy)	3.34	NA / 189248	3.33	NA / 630897
Radiation exposure - Mean DLP	Overall	94.83	NA / 193322	94.67	NA / 644565
	underweight (BMI <18.5)(mGy-cm)	70.41	NA / 4663	70.62	NA / 15624
	normal (BMI of 18.5-24.9)(mGy-cm)	77.15	NA / 45958	76.81	NA / 152692
	overweight (BMI of 25-29.9)(mGy-cm)	89.26	NA / 61111	89.30	NA / 203641
	obese class I (BMI of 30-34.9)(mGy-cm)	104.69	NA / 40606	104.68	NA / 135827
	obese class II (BMI of 35-39.9)(mGy-cm)	1.00	NA / 18218	1.00	NA / 61109
	obese class III (BMI of 40 or greater)(mGy-cm)	130.29	NA / 12592	129.63	NA / 41947
	routine chest exam (mGy-cm)	144.09	NA / 2774	141.72	NA / 9239
	low dose CT chest exam (mGy-cm)	94.12	NA / 189454	94.00	NA / 631603
Abnormal Interpretation Rate (%)	(Lung-RADS 3, 4a, 4b, 4x)	13.53	26482 / 195712	13.58	88610 / 652366
	Abnormal Interpretation Rate, at baseline exam (%)	16.47	15404 / 93514	16.61	51723 / 311480
	Abnormal Interpretation Rate, at annual exam (%)	10.73	10539 / 98251	10.69	35028 / 327777
Cancer Detection Rate (CDR) per 1000		2.79	546 / 195712	2.82	1842 / 652366

***Facility 100853 National Comparison
Jan-Dec 2020 with follow-up through Mar 2021***

		2020			
Measure		Your Facility (100853)		All LCSR	
		Rate	Num-Den	Rate	Num-Den
	prevalent cancers, detected at baseline exam	3.46	324 / 93514	3.47	1081 / 311480
	incident cancers, detected at annual exam	2.36	232 / 98251	2.49	815 / 327777
	stage 0	NA	NA / 561	17	NA / 1925
	stage IA, IA1, IA2, IA3, IB	39.39	221 / 561	38.65	744 / 1925
	stage IIA, IIB	7.13	40 / 561	8.05	155 / 1925
	stage IIIA, IIIB, IIIC	14.80	83 / 561	14.18	273 / 1925
	stage IV, IVA, IVB	9.98	56 / 561	9.61	185 / 1925
	stage unknown	27.63	155 / 561	28.62	551 / 1925
	presumptive case	NA	0 / 0	65.01	1924 / 652366
Positive Predictive Value 1 (PPV1)(%)		2.06	546 / 26482	2.08	1842 / 88610
	lung cancers detected on percutaneous biopsies (%)	61.72	266 / 431	60.09	843 / 1403
	lung cancers detected on bronchoscopies (%)	47.77	139 / 291	49.27	504 / 1023
	surgically detected lung cancers (%)	82.28	195 / 237	81.89	701 / 856
Positive Predictive Value 2a (PPV2a) (%)		0.64	137 / 21491	0.67	480 / 72057
Positive Predictive Value 2b (PPV2b) (%)		8.19	409 / 4991	8.23	1362 / 16553
Positive Predictive Value 3 (PPV3) (%)		65.24	396 / 607	65.01	1312 / 2018

***Facility 100853: Regional Comparison
Jan-Dec 2020 with follow-up through Mar 2021***

		2020							
Measure		Your Facility (100853)		Metropolitan		Freestanding		Missing	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
All Exams		.	195712	.	265154	.	140783	.	
Appropriateness of screening by USPSTF criteria (%)		91.17	178424 / 195712	90.69	240469 / 265154	89.31	125729 / 140783		
Smoking cessation counselling offered (%)		75.14	147049 / 195712	74.22	196793 / 265154	75.63	106470 / 140783		
	counselling offered among current smokers (%)	81.64	90982 / 111438	80.54	119281 / 148101	81.19	64460 / 79397		
Radiation exposure - Mean CTDIvol	Overall (mGy)	3.36	NA / 193108	3.50	NA / 262132	2.92	NA / 137926		
	underweight (BMI <18.5)(mGy)	2.44	NA / 4648	2.47	NA / 6212	2.03	NA / 3161		
	normal (BMI of 18.5-24.9)(mGy)	2.59	NA / 45891	2.73	NA / 63302	2.35	NA / 34523		
	overweight (BMI of 25-29.9)(mGy)	3.15	NA / 61049	3.25	NA / 83374	2.76	NA / 45143		
	obese class I (BMI of 30-34.9)(mGy)	3.74	NA / 40572	3.99	NA / 54408	3.29	NA / 27952		
	obese class II (BMI of 35-39.9)(mGy)	3.89	NA / 18211	4.04	NA / 24088	3.17	NA / 11552		
	obese class III (BMI of 40 or greater)(mGy)	4.60	NA / 12579	4.78	NA / 16717	3.59	NA / 8514		
	routine chest exam (mGy)	4.48	NA / 2765	4.15	NA / 5093	4.16	NA / 1172		
	low dose CT chest exam (mGy)	3.34	NA / 189248	3.49	NA / 256484	2.91	NA / 135454		
Radiation exposure - Mean DLP	Overall	94.83	NA / 193322	94.49	NA / 262311	93.50	NA / 137753		
	underweight (BMI <18.5)(mGy-cm)	70.41	NA / 4663	69.62	NA / 6231	70.17	NA / 3160		
	normal (BMI of 18.5-24.9)(mGy-cm)	77.15	NA / 45958	76.67	NA / 63400	77.31	NA / 34502		
	overweight (BMI of 25-29.9)(mGy-cm)	89.26	NA / 61111	89.28	NA / 83463	88.98	NA / 45116		
	obese class I (BMI of 30-34.9)(mGy-cm)	104.69	NA / 40606	104.46	NA / 54468	104.57	NA / 27947		
	obese class II (BMI of 35-39.9)(mGy-cm)	1.00	NA / 18218	1.00	NA / 24117	1.00	NA / 11549		
	obese class III (BMI of 40 or greater)(mGy-cm)	130.29	NA / 12592	129.30	NA / 16730	124.27	NA / 8510		
	routine chest exam (mGy-cm)	144.09	NA / 2774	128.11	NA / 5101	136.08	NA / 1172		

Facility 100853: Regional Comparison
Jan-Dec 2020 with follow-up through Mar 2021

		2020							
Measure		Your Facility (100853)		Metropolitan		Freestanding		Missing	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
	low dose CT chest exam (mGy-cm)	94.12	NA / 189454	93.81	NA / 256655	93.20	NA / 135281		
Abnormal Interpretation Rate (%)	(Lung-RADS 3, 4a, 4b, 4x)	13.53	26482 / 195712	13.23	35073 / 265154	13.91	19586 / 140783		
	Abnormal Interpretation Rate, at baseline exam (%)	16.47	15404 / 93514	15.85	19794 / 124871	16.07	11376 / 70812		
	Abnormal Interpretation Rate, at annual exam (%)	10.73	10539 / 98251	10.76	14462 / 134367	11.44	7542 / 65902		
Cancer Detection Rate (CDR) per 1000		2.79	546 / 195712	2.76	731 / 265154	1.70	240 / 140783		
	prevalent cancers, detected at baseline exam	3.46	324 / 93514	3.24	404 / 124871	2.20	156 / 70812		
	incident cancers, detected at annual exam	2.36	232 / 98251	2.55	343 / 134367	1.43	94 / 65902		
	stage 0	NA	NA / 561	4	NA / 752	3	NA / 252		
	stage IA, IA1, IA2, IA3, IB	39.39	221 / 561	45.08	339 / 752	36.51	92 / 252		
	stage IIA, IIB	7.13	40 / 561	8.24	62 / 752	8.33	21 / 252		
	stage IIIA, IIIB, IIIC	14.80	83 / 561	13.96	105 / 752	11.51	29 / 252		
	stage IV, IVA, IVB	9.98	56 / 561	10.24	77 / 752	7.14	18 / 252		
	stage unknown	27.63	155 / 561	21.94	165 / 752	35.32	89 / 252		
	presumptive case	NA	0 / 0	64.80	753 / 265154	57.34	256 / 140783		
Positive Predictive Value 1 (PPV1)(%)		2.06	546 / 26482	2.08	731 / 35073	1.23	240 / 19586		
	lung cancers detected on percutaneous biopsies (%)	61.72	266 / 431	61.52	307 / 499	52.66	99 / 188		
	lung cancers detected on bronchoscopies (%)	47.77	139 / 291	47.83	198 / 414	42.50	51 / 120		
	surgically detected lung cancers (%)	82.28	195 / 237	81.59	319 / 391	81.82	99 / 121		
Positive Predictive Value 2a (PPV2a) (%)		0.64	137 / 21491	0.71	202 / 28447	0.41	66 / 16106		

Facility 100853: Regional Comparison
Jan-Dec 2020 with follow-up through Mar 2021

		2020							
Measure		Your Facility (100853)		Metropolitan		Freestanding		Missing	
		Rate	Num-Den	Rate	Num-Den	Rate	Num-Den	Rate	Num-Den
Positive Predictive Value 2b (PPV2b) (%)		8.19	409 / 4991	7.98	529 / 6626	5.00	174 / 3480		
Positive Predictive Value 3 (PPV3) (%)		65.24	396 / 607	64.80	508 / 784	57.34	168 / 293		

Maintenance of Certification (MOC): Practice Quality Improvement (PQI)

With the implementation of Continuous Certification and its annual look-back approach, diplomates must have completed at least one PQI Project or Participatory Quality Improvement Activity in the previous three years at each annual look-back. A PQI Project or Activity may be conducted repeatedly or continuously to meet PQI

requirements. (<https://www.theabr.org/diagnostic-radiology/maintenance-of-certification/improvement-medical-practice/participatory-activities>)

The National Radiology Data Registry has been approved by the American Board of Radiology for fulfilling MOC Part IV requirements. The names of the physicians are listed below.

NPI	Last Name	First Name
1013962497	Berland	Lincoln
1255433280	Thorwarth	William
1376568014	Geis	John
1740332030	Hillman	Bruce
1780697441	Rosen	Donald
1780766014	Cheng	Viola

Promote your participation in NRDR™! Download your marketing toolkit today.

acr.org/LCSRtoolkit

CONTACT US

1.800.227.5463, ext. 3535
nrdre@acr.org | nrdre.acr.org

